TSPAN17

Across TCGA pan-cancer cohorts, TSPAN17 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TSPAN17 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TSPAN17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TSPAN17 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

MESO, PRAD, and UCEC are the cancer types where TSPAN17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.830	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TSPAN17–MESO (DFS)

Open the MESO breakdown →